t(14;18) translocations and risk of follicular lymphoma

Journal of the National Cancer Institute - Monographs

Volumn , Issue 39, 2008, Pages 48-51

  Rabkin, Charles S ^a   Hirt, Carsten ^a,b   Janz, Siegfried ^a   Dölken, Gottfried ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN; IMMUNOGLOBULIN M; MYELIN; PLACEBO; PROTEIN BCL 2; RECOMBINASE; RITUXIMAB; TUMOR MARKER;

BURKITT LYMPHOMA; CANCER RISK; CARCINOGENESIS; CELL CLONE; CELL MATURATION; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; CONFERENCE PAPER; EARLY DIAGNOSIS; FOLLICULAR LYMPHOMA; HEMOLYTIC ANEMIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN M NEUROPATHY; IMMUNOPHENOTYPING; MALIGNANT TRANSFORMATION; MINIMAL RESIDUAL DISEASE; NEUROPATHY; NONHODGKIN LYMPHOMA; PERIPHERAL LYMPHOCYTE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SEQUENCE ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; HUMANS; LYMPHOMA, FOLLICULAR; RISK FACTORS; TRANSLOCATION, GENETIC;

EID: 52149096949     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgn002     Document Type: Conference Paper

References (29)

1. Hirt C, Dolken G. Quantitative detection of t(14;18)-positive cells in patients with follicular lymphoma before and after autologous bone marrow transplantation. Bone Marrow Transplant. 2000;25(4): 419-426.
2. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood. 2004;103(12):4416-4423.
3. McDonnell TJ, Deane N, Platt FM, et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989;57(1):79-88.
4. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature. 1991;349(6306):254-256.
5. Limpens J, de Jong D, van Krieken JH, et al. Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene. 1991;6(12): 2271-2276.
6. Janz S, Potter M, Rabkin CS. Lymphoma-and leukemia-associated chromosomal translocations in healthy individuals. Genes Chromosomes Cancer. 2003;36(3):211-223.
7. Liu Y, Hernandez AM, Shibata D, Cortopassi GA. BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA. 1994;91: 8910-8914.
8. Ji W, Qu GZ, Ye P, Zhang XY, Halabi S, Ehrlich M. Frequent detection of bcl-2/JH translocations in human blood and organ samples by a quantitative polymerase chain reaction assay. Cancer Res. 1995;55(13): 2876-2882.
9. Bell DA, Liu Y, Cortopassi GA. Occurrence of bcl-2 oncogene translocation with increased frequency in the peripheral blood of heavy smokers. J Natl Cancer Inst. 1995;87:223-224.
10. Zuckerman E, Zuckerman T, Sahar D, et al. The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood. 2001;97(6): 1555-1559.
11. Roulland S, Lebailly P, Lecluse Y, Briand M, Pottier D, Gauduchon P. Characterization of the t(14;18) BCL2-IGH translocation in farmers occupationally exposed to pesticides. Cancer Res. 2004;64(6):2264-2269.
12. Bentham G, Wolfreys AM, Liu Y, et al. Frequencies of hprt(-) mutations and bcl-2 translocations in circulating human lymphocytes are correlated with United Kingdom sunlight records. Mutagenesis. 1999;14(6):527-532
13. Hartge P, Devesa SS, Grauman D, Fears TR, Fraumeni JF Jr. Non-Hodgkin's lymphoma and sunlight. J Natl Cancer Inst. 1996;88(5):298-300
14. Freedman DM, Zahm SH, Dosemeci M. Residential and occupational exposure to sunlight and mortality from non-Hodgkin's lymphoma: Composite (threefold) case-control study. BMJ. 1997;314(7092):1451-1455
15. Dolken L, Schuler F, Dolken G. Quantitative detection of t(14;18)-positive cells by real-time quantitative PCR using fluorogenic probes. Biotechniques. 1998;25(6):1058-1064.
16. Dolken G, Illerhaus G, Hirt C, Mertelsmann R. BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol. 1996;14(4):1333-1344.
17. Yasukawa M, Bando S, Dolken G, et al. Low frequency of BCL-2/J(H) translocation in peripheral blood lymphocytes of healthy Japanese individuals. Blood. 2001;98(2):486-488.
18. Biagi JJ, Seymour JF. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood. 2002;99(12 4265-4275.
19. Muller JR, Janz S, Goedert JJ, Potter M, Rabkin CS. Persistence of immunoglobulin heavy chain/c-myc recombination-positive lymphocyte clones in the blood of human immunodefeciency virus-infected homosexual men Proc Natl Acad Sci USA. 1995;92:6577-6581.
20. Liu Y, Cortopassi G, Goedert JJ, Rabkin CS. Frequency of Bcl-2 rearrangements in peripheral blood of HIV-infected individuals [letter; comment]. Br J Hematol. 1997;99:465-466.
21. Dolken L, Schuler F, Dolken G. Frequency of BCL-2/J(H) translocation in healthy males exposed to low-level radiation in comparison to age-matched health controls. Blood. 2002;100(4):1513-1514.
22. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14; chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science. 1985;229(4720):1390-1393.
23. Roulland S, Navarro JM, Grenot P, et al. Follicular lymphoma-like B cells in healthy individuals: A novel intermediate step in early lymphomagenesis. J Exp Med. 2006;203(11):2425-2431.
24. Hirt C, Doelken G, Janz S, Rabkin CS. Distribution of t(14;18)-positive, putative lymphoma precursor cells among B cell subsets in healthy individuals. Br J Hematol. 2007;138(3):349-353.
25. McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park). 1998;12(12):1763-1769.
26. Foran JM, Gupta RK, Cunningham D, et al. A UK multicentre phase study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response Br J Hematol. 2000;109(1):81-88.
27. Colombat P, Salles G, Brousse N, et al. Rituximab(anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 2001;97(1):101-106.
28. Maloney DG. Preclinical and phase I and II trials of rituximab. Semin Oncol. 1999;26(5)(suppl 14):74-78.
29. Kieseier BC, Dalakas MC, Hartung HP. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology. 2002;59(12)(suppl 6): S7-S12.